749902-11-2

Basic information

• Product Name: 2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE
• Synonyms: 2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE;2-(3-METHOXYPHENYL)-1,3-THIAZOLE-4-CARBALDEHYDE
• CAS NO: 749902-11-2
• Molecular Formula: C11H9NO2S
• Molecular Weight: 219.26
• Mol File: 749902-11-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 397.668 °C at 760 mmHg
• Flash Point: 194.303 °C
• Appearance: /
• Density: 1.267 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.619
• PKA: 0.12±0.50(Predicted)
• CAS DataBase Reference: 2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE(749902-11-2)
• EPA Substance Registry System: 2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE(749902-11-2)

Safety Data

• Hazardous Substances Data: 749902-11-2(Hazardous Substances Data)

Usage

General Description

2-(3-methoxy-phenyl)-thiazole-4-carbaldehyde, also known as thiazole-4-carbaldehyde, is a chemical compound with the molecular formula C11H9NOS. It is a yellow crystalline powder with a molecular weight of 211.26 g/mol. 2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE is used as a reagent in organic synthesis and pharmaceutical research, particularly in the development of thiazole-based drugs. It is also used as a building block for the synthesis of various types of heterocyclic compounds. Thiazole-4-carbaldehyde has potential applications in medicinal chemistry and drug discovery due to its structural similarity to natural products and its ability to modulate biological pathways. It is important to handle this compound with care, as it may present certain hazards if not properly managed.

InChI:InChI=1/C11H9NO2S/c1-14-10-4-2-3-8(5-10)11-12-9(6-13)7-15-11/h2-7H,1H3

Upstream product

• 5198-80-1 2-bromothiazole-4-carbaldehyde 
• 10365-98-7 3-methoxyphenylboronic acid 

Relevant articles and documents

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family

The PIM family of serine/threonine kinases have become an attractive target for anti-cancer drug development, particularly for certain hematological malignancies. Here, we describe the discovery of a series of inhibitors of the PIM kinase family using a high throughput screening strategy. Through a combination of molecular modeling and optimization studies, the intrinsic potencies and molecular properties of this series of compounds was significantly improved. An excellent pan-PIM isoform inhibition profile was observed across the series, while optimized examples show good selectivity over other kinases. Two PIM-expressing leukemic cancer cell lines, MV4-11 and K562, were employed to evaluate the in vitro anti-proliferative effects of selected inhibitors. Encouraging activities were observed for many examples, with the best example (44) giving an IC50 of 0.75 μM against the K562 cell line. These data provide a promising starting point for further development of this series as a new cancer therapy through PIM kinase inhibition.